Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | CREBBP | Q92793 | 9/20 | 0.58 |
| ▸ | EP300 | Q09472 | 7/20 | 0.58 |
| ▸ | BRD4 | O60885 | 4/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RBP4 | P02753 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10805635 | 0.87 | MAPK1 (1.00) | MAPK1CREBBPEP300BRD4KCNK3 | |
| SCHEMBL10819101 | 0.87 | CREBBP (0.67) | MAPK1CREBBPEP300BRD4KCNK3 | |
| SCHEMBL2977256 | 0.86 | MAPK1 (0.57) | MAPK1CREBBPEP300BRD4NPC1 | |
| SCHEMBL10801839 | 0.85 | MAPK1 (0.76) | MAPK1CREBBPEP300BRD4NPC1 | |
| SCHEMBL10817743 | 0.85 | MAPK1 (0.80) | MAPK1CREBBPEP300BRD4NPC1 | |
| SCHEMBL2982055 | 0.84 | MAPK1 (0.78) | MAPK1CREBBPEP300BRD4NPC1 | |
| SCHEMBL2979198 | 0.84 | MAPK1 (0.78) | MAPK1CREBBPEP300BRD4NPC1 | |
| SCHEMBL2977735 | 0.84 | MAPK1 (0.78) | MAPK1CREBBPEP300BRD4NPC1 | |
| SCHEMBL10818694 | 0.84 | MAPK1 (0.77) | MAPK1CREBBPEP300BRD4 | |
| SCHEMBL16365974 | 0.84 | MAPK1 (0.77) | MAPK1CREBBPEP300BRD4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598410-B2 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them | SANOFI (FR) | 2017-03-21 | — | — | US | disclosed |
| US-9598410-B2 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-C]pyridines, their use as medicament, and pharmaceutical preparations comprising them | SANOFI (FR) | 2017-03-21 | — | — | US | disclosed |
| US-20160060259-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | SANOFI (FR) | 2016-03-03 | — | — | US | disclosed |
| US-20160060259-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | SANOFI (FR) | 2016-03-03 | — | — | US | disclosed |
| EP-2755973-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI SA (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2755973-B1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI SA (FR) | 2015-11-04 | — | — | EP | disclosed |
| EP-2755972-B1 | INDANYL-SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI SA (FR) | 2015-10-28 | — | — | EP | disclosed |
| EP-2755972-B1 | INDANYL-SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI SA (FR) | 2015-10-28 | — | — | EP | disclosed |
| US-9127001-B2 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| US-9127001-B2 | Substituted 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them | SANOFI (FR) | 2015-09-08 | — | — | US | disclosed |
| US-20030078419-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-04-24 | — | — | US | disclosed |
| US-20030073672-A1 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030069240-A1 | Method for treating allergies using substituted pyrazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-10 | — | — | US | disclosed |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-08-22 | — | — | US | disclosed |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | BUTLER CHRISTOPHER R (US) | 2002-05-09 | — | — | US | disclosed |
| US-20020040020-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002020012-A2 | METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002020011-A2 | A METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014314-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002014315-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060259-A1 | Substituted 4,5,6,7-Tetrahydro-1H-Pyrazolo[4,3-C]Pyridines, Their Use as Medicament, and Pharmaceutical Preparations Comprising Them | KCNA1, KCNT1, CACNA1I | MAPK1 388/4885CREBBP 4121/4885EP300 2133/4885 |
| US-20030078419-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MAPK1 4426/4885CREBBP 3211/4885EP300 756/4885 |
| US-20030069240-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MAPK1 4370/4885CREBBP 1005/4885EP300 84/4885 |
| US-20020115656-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MAPK1 4370/4885CREBBP 1005/4885EP300 84/4885 |
| US-20030073672-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MAPK1 4370/4885CREBBP 1005/4885EP300 84/4885 |
| US-20020055497-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MAPK1 4370/4885CREBBP 1005/4885EP300 84/4885 |
| US-20020040020-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MAPK1 4426/4885CREBBP 3211/4885EP300 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.